Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LifeTech Scientific Corporation ( (HK:1302) ) has issued an announcement.
LifeTech Scientific Corporation announced the official approval of its Ankura™ Aortic Stent Graft System by the China National Medical Products Administration. This system, co-developed with Fuwai Hospital, is the first of its kind to be applicable to the chimney technique, offering a safer and more effective treatment for aortic arch lesions. The approval marks a significant advancement in the company’s comprehensive solutions for aortic arch reconstruction and positions LifeTech to expand its market presence by meeting urgent clinical needs and benefiting a broad patient base.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation operates in the medical device industry, focusing on innovative endovascular solutions. The company develops and manufactures products such as the Ankura™ Aortic Stent Graft System, aiming to improve treatment options for patients with cardiovascular conditions.
YTD Price Performance: 2.88%
Average Trading Volume: 22,541,852
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$6.39B
For an in-depth examination of 1302 stock, go to TipRanks’ Stock Analysis page.